Badanie entrektynibu (Rxdx-101) u dzieci i młodzieży z miejscowo zaawansowanymi lub przerzutowymi litymi lub pierwotnymi guzami OUN i/lub u których nie ma zadowalających możliwości leczenia (STARTRK-NG)
Otwarte badanie fazy 1/2 z eskalacją dawki i rozszerzeniem entrektynibu (Rxdx-101) u dzieci z miejscowo zaawansowanymi lub przerzutowymi litymi lub pierwotnymi guzami OUN i/lub u pacjentów bez zadowalających możliwości leczenia
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Faza
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Beijing, Chiny
- Beijing Children's Hospital, Capital Medical University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chiny, 200082
- Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
-
-
-
-
-
Lyon, Francja, 69373
- Centre Leon Berard
-
Marseille, Francja, 13385
- Hôpital de la Timone, Oncologie Pédiatrique
-
-
-
-
-
Madrid, Hiszpania, 28009
- Hospital Infantil Universitario Nino Jesus
-
-
-
-
-
Hong Kong, Hongkong, 00000
- Hong Kong Children's Hospital
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Niemcy, 69120
- Universitaetsklinikum Heidelberg
-
-
-
-
California
-
La Jolla, California, Stany Zjednoczone, 92093-0706
- University of California San Diego
-
San Francisco, California, Stany Zjednoczone, 94158
- UCSF Benioff Children's Hospital
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- Children's Hospital Colorado
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30322
- Egleston Children's Hospital at Emory University Atlanta
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60637
- University of Chicago
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21205
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02215
- Dana Farber Cancer Institute
-
-
Missouri
-
St Louis, Missouri, Stany Zjednoczone, 63110
- Washington University,St. Louis Children's Hospital
-
-
New York
-
New York, New York, Stany Zjednoczone, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus, Ohio, Stany Zjednoczone, 43205
- Nationwide Children's Hospital
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone, 97239
- Oregon Health & Science Uni
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
- Children's Hospital of Philadelphia
-
-
Tennessee
-
Memphis, Tennessee, Stany Zjednoczone, 38105
- St. Jude Children'S Research Hospital
-
-
Texas
-
Houston, Texas, Stany Zjednoczone, 77030
- Texas Children's Cancer and Hematology Center
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84113
- Primary Children's Hospital
-
-
-
-
Lombardy
-
Milan, Lombardy, Włochy, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
-
-
-
-
London, Zjednoczone Królestwo, SW3 6JJ
- Royal Marsden Hospital (Sutton)
-
Newcastle upon Tyne, Zjednoczone Królestwo, NE1 4LP
- Royal Victoria Infirmary
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Disease status:
-
Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1
-
Phase 2 portion:
- Part B: Participants must have measurable or evaluable disease, as defined by RANO
- Part C (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale
- Part D: Participants must have measurable or evaluable disease, as defined by RECIST v1.1
- Part E (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale or RANO
-
-
Tumor type:
-
Phase 1 portion:
* Part A: Relapsed or refractory extracranial solid tumors
-
Phase 2 portion
- Part B: Primary brain tumors with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
- Part D: Extracranial solid tumors (including NB) with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
-
-
Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse
-
Archival tumor tissue from diagnosis or, preferably, at relapse
-
Performance status: Lansky or Karnofsky score ≥ 60% and minimum life expectancy of at least 4 weeks
-
Prior therapy: Participants must have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options for solid tumors and primary CNS tumors that are neurotrophic tyrosine receptor kinase (NTRK) or ROS1 fusion-positive
-
Participants must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment
-
Adequate organ and neurologic function
-
Females of childbearing potential must have a negative serum pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation. Agreement to remain abstinent or use use combined contraceptive methods prior to study entry, for the duration of study participation and in the following 90 days after discontinuation of study treatment.
-
For male participants with a female partner of childbearing potential or a pregnant female partner: Agreement to remain abstinent or use a condom during the treatment period and for at least 3 months after the last dose of study drug
Exclusion Criteria:
- Receiving other experimental therapy
- Known congenital long QT syndrome
- History of recent (3 months) symptomatic congestive heart failure or ejection fraction ≤50% at screening
- Known active infections
- Familial or personal history of congenital bone disorders, bone metabolism alterations or osteopenia
- Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within 14 days of first dose.
- Prior treatment with approved or investigational TRK or ROS1 inhibitors
- Known hypersensitivity to entrectinib or any of the other excipients of the investigational medicinal product
- Patients with NB with bone marrow space-only disease
- Incomplete recovery from acute effects of any surgery prior to treatment.
- Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
- Other severe acute or chronic medical or psychiatric condition or lab abnormality that may increase the risk associated with study participation, drug administration or may interfere with the interpretation of study results.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Aktywny komparator: Extracranial solid tumors harboring NTRK1/2/3,
Arm closed for further enrollment ROS1, ALK non-gene fusion molecular alterations Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Inne nazwy:
|
|
Aktywny komparator: CNS tumors harboring- NTRK1/2/3, ROS1, ALK
Arm closed for further enrollment molecular alterations, including gene fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Inne nazwy:
|
|
Aktywny komparator: Neuroblastoma
Arm closed for further enrollment Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Inne nazwy:
|
|
Aktywny komparator: Non-neuroblastoma, extracranial solid tumors
Arm closed for further enrollment harboring - NTRK1/2/3, ROS1, ALK gene fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Inne nazwy:
|
|
Aktywny komparator: Any participant unable to swallow capsules
Arm closed for further enrollment Any participant who otherwise meet all other eligibility criteria Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Inne nazwy:
|
|
Aktywny komparator: Expansion: CNS tumors harboring NTRK1/2/3, ROS1
gene fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Inne nazwy:
|
|
Aktywny komparator: Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1
NTRK 1,2,3 and ROS1 fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Maximum Tolerated Dose (MTD)
Ramy czasowe: Approximately 6 months
|
Assessed by National Cancer Institute Common Terminology for Adverse Events Criteria (NCI CTCAE v4.03) |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) of F1 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Ramy czasowe: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Ramy czasowe: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric In Participants Dosed Via Feeding Tube (Nasogastric Tube Or Gastric Tube)
Ramy czasowe: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) Of Minitablets/F15 Formulation In Pediatric Participants Unable To Swallow Intact Capsules
Ramy czasowe: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Cohort B: Objective Response Rate (ORR)
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR |
Approximately 6 months
|
|
Cohort D: ORR
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR |
Approximately 6 months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03
Ramy czasowe: Approximately 24 months
|
AE, ECG and Labs assessed by NCI CTCAE v4.03 |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using F1 Formulation
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using F06 Formulation given intact
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using F06 Formulation administered via feeding tube
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using minitablets/F15
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using F1 Formulation
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using F06 Formulation given intact
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using F06 Formulation administered via feeding tube
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using minitablets/F15
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using F1 Formulation
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using F06 Formulation given intact
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using F06 Formulation administered via feeding tube
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using minitablets/F15
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using F1 Formulation
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using F06 Formulation given intact
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using F06 Formulation administered via feeding tube
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using minitablets/F15
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using F1 Formulation
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using F06 Formulation given intact
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using F06 Formulation administered via feeding tube
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using minitablets/F15
Ramy czasowe: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Cohort A, D, or E: Clinical Benefit Rate (CBR)
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: CBR
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: CBR
Ramy czasowe: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Progression-free Survival (PFS)
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: PFS
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: PFS
Ramy czasowe: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Overall Survival (OS)
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 |
Approximately 6 months
|
|
Cohort B or E: OS
Ramy czasowe: Approximately 6 months
|
Assessed by RANO |
Approximately 6 months
|
|
Cohort A, D, or E: ORR
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: ORR
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: ORR
Ramy czasowe: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Time to response (TTR)
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: TTR
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: TTR
Ramy czasowe: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Duration of Response (DOR)
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: DOR
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: DOR
Ramy czasowe: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): ORR
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): ORR
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): ORR
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): ORR
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): ORR
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): ORR
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): DOR
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): DOR
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): DOR
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): DOR
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): DOR
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): DOR
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): TTR
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): TTR
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): TTR
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): TTR
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): TTR
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): TTR
Ramy czasowe: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Ramy czasowe: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Dyrektor Studium: Clinical Trials, Hoffmann-La Roche
Publikacje i pomocne linki
Publikacje ogólne
- Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022 Oct 3;24(10):1776-1789. doi: 10.1093/neuonc/noac087.
- Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11.
- Desai AV, Bagchi A, Armstrong AE, van Tilburg CM, Basu EM, Robinson GW, Wang H, Casanova M, Andre N, Campbell-Hewson Q, Wu Y, Cardenas A, Ci B, Ryklansky C, Devlin CE, Meneses-Lorente G, Wulff J, Hutchinson KE, Gajjar A, Fox E. Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 2;220:115308. doi: 10.1016/j.ejca.2025.115308. Epub 2025 Feb 22.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Szacowany)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
- Pediatryczny
- Nawrót
- Oporny
- Mięsak Ewinga
- Rdzeniak zarodkowy
- Guz lity
- Rak z przerzutami
- Mięsak
- Nerwiak zarodkowy : neuroblastoma
- Rak brodawkowaty tarczycy
- Guzy OUN
- ROS1
- NTRK
- ALK
- Nowotwór mózgu
- NTRK1
- NTRK2
- NTRK3
- TRK
- Kinaza tyrozynowa
- Rearanżacja genów
- Włókniakomięsak niemowlęcy
- Wydzielniczy rak piersi
- Wrodzona nerczak mezoblastyczny
- Glejaka Pontyjskiego
- Guzy glejowe
- Rak ślinianek (MASC)
- Guz Wilmsa (anaplastyczny)
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby układu hormonalnego
- Choroby jamy ustnej
- Choroby Stomatognatyczne
- Choroby mózgu
- Choroby ośrodkowego układu nerwowego
- Choroby Układu Nerwowego
- Procesy patologiczne
- Nowotwory układu moczowo-płciowego
- Nowotwory według lokalizacji
- Nowotwory
- Choroby układu moczowo-płciowego u mężczyzn
- Choroby nerek
- Choroby Urologiczne
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Atrybuty choroby
- Choroby genetyczne, wrodzone
- Nowotwory według typu histologicznego
- Nowotwory tarczycy
- Nowotwory gruczołów dokrewnych
- Nowotwory głowy i szyi
- Nowotwory gruczołowe i nabłonkowe
- Rak gruczołowy
- Procesy Nowotworowe
- Nowotwory urologiczne
- Rak
- Nowotwory neuroepitelialne
- Nowotwory neuroektodermalne
- Nowotwory, komórki rozrodcze i embrionalne
- Nowotwory, tkanka nerwowa
- Nowotwory Układu Nerwowego
- Nowotwory nerek
- Choroby gruczołów ślinowych
- Zespoły nowotworowe, dziedziczne
- Nowotwory, tkanka łączna i miękka
- Guzy neuroektodermalne, pierwotne, obwodowe
- Nowotwory neuroektodermalne, prymitywne
- Kostniakomięsak
- Nowotwory, tkanka kostna
- Nowotwory, tkanka łączna
- Nowotwory złożone i mieszane
- Choroby tarczycy
- Gruczolakorak, brodawkowaty
- Nowotwory jamy ustnej
- Wrodzone, dziedziczne i noworodkowe choroby i nieprawidłowości
- Stany patologiczne, oznaki i objawy
- Rak tarczycy, brodawkowaty
- Nawrót
- Przerzuty nowotworu
- Glejak
- Nerwiak zarodkowy : neuroblastoma
- Mięsak, Ewing
- Mięsak
- Nowotwory mózgu
- Nowotwory ośrodkowego układu nerwowego
- Rdzeniak zarodkowy
- Guz Wilmsa
- Nefroma, mezoblastyczna
- Nowotwory gruczołów ślinowych
- Entrectinib
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- RXDX-101-03
- CO40778 (Inny identyfikator: Hoffmann-La Roche)
- 2023-505088-35-00 (Ctis)
- 2023 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .